<unk> , sold under the brand name Recarbrio, is a fixed-dose combination medication used as an antibiotic. In 2019, it was approved for use in the United States for the treatment of complicated urinary tract and complicated intra-abdominal infections. It is administered via intravenous injection. The most common adverse reactions include nausea, diarrhea, headache, fever and increased liver enzymes. The most common adverse reactions observed in people treated for hospital-acquired bacterial pneumonia and ventilator-associated bacterial pneumonia (HABP/VABP) include increased aspartate/alanine aminotransferases (increased liver enzymes), anemia, diarrhea, hypokalemia (low potassium), and hyponatremia (low sodium).
Imipenem/cilastatin/relebactam
Meropenem/vaborbactam
Ceftazidime/avibactam
Teicoplanin
Resistin
Neomycin/polymyxin B/bacitracin
Fosfomycin/tobramycin
Meropenem